Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia

English

Dr. Erba's research focus is on clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia. Specifically, he has been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy. Dr. Erba has been an active member of teams of doctors that have brought new treatments to people with AML, such as oral drugs that inactivate FLT3 and IDH.